Adagene Inc. (FRA:978)
3.260
0.00 (0.00%)
At close: Apr 24, 2026
Adagene Revenue
In the year 2025, Adagene had annual revenue of $7.67M USD with 7,332.76% growth. Adagene had revenue of $7.67M in the half year ending December 31, 2025, with 840.35% growth.
Revenue
$7.67M
Revenue Growth
+7,332.76%
P/S Ratio
32.29
Revenue / Employee
$59.93K
Employees
128
Market Cap
210.96M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.76% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biotest Aktiengesellschaft | 635.20M |
| Darwin AG | 27.35M |
| Paion AG | 14.81M |
| 2invest AG | 8.89M |
| co.don AG | 6.24M |
| MagForce AG | 1.08M |
| Biomark Diagnostics | 57.01K |
| bioXXmed AG | 20.49K |